Now Enrolling Learn More Now Enrolling Learn More Now Enrolling Learn More Latest News Nov 18, 2021 Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Education and Research of Epidermolysis Bullosa View Press Release Nov 17, 2021 Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference View Press Release Nov 16, 2021 Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference View Press Release View All Our inspiration Learn More Pipeline Our clinical-stage therapies are designed to deliver functional copies of affected genes to cells using gene transfer technologies. Explore R&D EB-101 In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-102 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). Learn More ABO-101 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type B (MPS IIIB). Learn More Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
